The Relative Strength (RS) Rating for ACM Research Cl A moved up into a new percentile Monday, as it got a lift from 67 to 72.
IBD's proprietary rating tracks share price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if ACM Research Cl A can continue to rebound and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
ACM Research Cl A is now considered extended and out of buy range after clearing an 18.75 buy point in a second-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company showed 11% EPS growth in the latest quarterly report, while sales growth came in at 21%. Keep an eye out for the company's next round of numbers on or around Feb. 21.
The company holds the No. 4 rank among its peers in the Electronics-Semiconductor Equipment industry group. Nova is the No. 1-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
